Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Safety and Tolerability Study of Optimized Doses of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

NCT03444038 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT03444038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03444038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Safety and Tolerability Study of Optimized Doses of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Lead sponsor
Neurocrine Biosciences
Phase
Phase 2
Overall status
Completed
Start date
February 8, 2018
Completion date
July 12, 2019
Enrollment
85 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

tourette syndrome